|Articles|September 9, 2021
Positioning Biobanking Assets for Maximum Value
Author(s)Crosstree
As precision medicine grows, so, too, does demand for biobanking services, offering both strategic and financial investors a significant opportunity for value creation.
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5